|
In a study published in the October 5, 2004 issue of Proceedings of the National Academy of Sciences USA, researchers at Dana Farber Cancer Institute and Brigham and Women's Hospital in Boston treated mice affected by myeloproliferative disease with PKC412, a new experimental highly specific drug that disables a switch in blood cancer cells that causes the uncontrolled division and growth of blood cells. The drug prolonged the life of the mice but did not cure the disease. The reseachers believe PKC412 may be effective in treating humans with MPD. |
